ASX & LSE Listing Update

Argent Biopharma Limited
29 November 2024
 

 

29 November 2024

 

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

 

ASX Delisting Update

and

Notice of Intention to Delist from the London Stock Exchange

 

Argent BioPharma, an innovative multidisciplinary drug discovery company within the biopharmaceutical sector, wishes to advise, that following a detailed review of both the listing requirements and costs associated with the transfer of all its ordinary shares, from the equity shares (international commercial companies secondary listing) category of the Official List maintained by the Financial Conduct Authority ("FCA") ("Official List"), to the equity shares (commercial companies) ("ESCC") category of the Official List, the Company has decided to retain its listing on the Australian Securities Exchange ("ASX") and apply to the FCA and the London Stock Exchange ("LSE")  to cancel the admission of Argent BioPharma's shares to listing in the International Commercial Companies Secondary Listing category of the Official List of the FCA and trading under the ticker "RGT" on the Main Market for listed securities of the LSE.

 

The Company hereby gives notice that, in an effort to streamline and simplify processes and increase administrative efficiencies, it will requested that (i) the FCA cancel the listing of the Company's ordinary shares of NPV ("Shares") on the equity shares international commercial companies secondary listing segment of the Official List of the FCA, and (ii) the LSE cancel the admission to trading of the Company's Shares on the main market for listed securities of the LSE (collectively, the "Delisting").

 

In accordance with UK Listing Rule 21.2.17, Argent BioPharma is required to give at least 20 business days' notice of the intended Delisting. It is expected the Delisting will become effective from 08:00 (GMT) on 31 December 2024. The last day of trading of Argent BioPharma shares on the LSE will be Monday, 31 December 2024.

 

As the Company is assigned to the equity shares international commercial companies secondary listing segment of the Official List, no shareholder approval is required for the Delisting. Following the Delisting, (i) it will no longer be possible to trade Shares on the LSE, and (ii) the Company will maintain its listings on the ASX and OTCQB Venture Market.

 

Any shareholder with questions regarding the Delisting is encouraged to consult their investment adviser or broker. The Company will provide an update to holders of its Depositary Interests, outlining how their holdings will be affected and the steps required to ensure the future tradability of their securities.

 

The Company's main operations and management are based in the EU, with a growing investor base in the United States of America. Looking ahead, Argent BioPharma may still look to explore opportunities to expand its accessibility to investors, including the potential for a dual listing on a United States based exchange.

 

 

-Ends-

 

 

 

Authorised for release by the board of directors, for further information please contact:

 

Argent BioPharma

Roby Zomer

CEO & Managing Director

+61 8 6555 2950

info@argentbiopharma.com

Argent BioPharma

Rowan Harland

Company Secretary

+61 8 6555 2950

info@argentbiopharma.com

 

About Argent BioPharma

 

Argent BioPharma Limited (the "Company") (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector.  The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the central nervous system ("CNS") and Immunology treatments.

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings